We recommend that future studies on inflammation and depression, including time series analyses of plasma aCL IgM titers, extend the timeframe for observation beyond the conventional clinical trial timeline (8–12 weeks) in order to establish sequential effects of treatment on the proinflammatory state of the patient as revealed in levels of inflammatory markers. The gene discussed is ACLY; the disease is depressive symptom measurement.